The 5-year relative survival rate for female breast cancer in the United States stands at 91.4%. Localized cases reach 99.3% while metastatic disease falls to 31.2%. Rates also vary by age group and molecular subtype.
Key Takeaways
- The 5-year breast cancer survival rate for women under 50 years in the US (2014-2020) is 89.2%
- For women 50-69 years, 5-year survival is 92.8% in US
- Women 70+ years 5-year breast cancer survival 88.1% US (2014-2020)
- Triple-negative breast cancer (TNBC) 5-year survival rate is 77% overall, dropping to 12% for metastatic
- HER2-positive breast cancer 5-year survival improved to 90.3% with targeted therapy (2014-2020 US)
- Luminal A subtype 5-year survival 91-95%
- The 5-year relative survival rate for all stages of female breast cancer combined in the United States from 2014-2020 is 91.4%
- The 10-year overall survival rate for breast cancer patients diagnosed between 2000-2010 in Europe is approximately 81%
- In Canada, the 5-year net survival rate for breast cancer in women from 2015-2017 is 88.6%
- The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) in the US (2014-2020) is 99.3%
- For regional breast cancer (spread to regional lymph nodes) 5-year survival in US (2014-2020) is 86.6%
- Distant metastatic breast cancer 5-year survival in US (2014-2020) is 31.2%
- Breast cancer patients receiving tamoxifen have 15% reduced mortality, translating to 84% 10-year survival for ER+
- Trastuzumab for HER2+ early breast cancer improves 5-year survival from 75% to 90%
- Radiation after lumpectomy increases 10-year survival by 3.6% to 91.7%
Across countries, 5 year breast cancer survival often exceeds 80%, highest with early detection and targeted care.
Related reading
01 · Category
Demographic Specific Survival Rates27 stats
01
The 5-year breast cancer survival rate for women under 50 years in the US (2014-2020) is 89.2%
02
For women 50-69 years, 5-year survival is 92.8% in US
03
Women 70+ years 5-year breast cancer survival 88.1% US (2014-2020)
04
US non-Hispanic White women 5-year survival 92.4%
05
US Black women 5-year breast cancer survival 81.7%
06
US Hispanic women 5-year survival 89.4%
07
Asian/Pacific Islander US women 5-year survival 94.5%
08
American Indian/Alaska Native women 5-year survival 85.2% US
09
In UK, women under 40 have 5-year survival of 82%
10
UK women 40-49 years breast cancer 5-year survival 90%
11
UK 50-69 years 5-year survival 91%
12
UK 70-79 years 5-year survival 86%
13
UK 80+ years breast cancer 5-year survival 70%
14
In Australia, younger women (<50) 5-year survival 91.2%
15
Older women (70+) Australia 5-year survival 86.5%
16
Indigenous Australian women breast cancer 5-year survival 75%
17
In Canada, women aged 20-49 5-year survival 89%
18
Canadian women 50-69 5-year survival 92%
19
In Brazil, Black women 5-year survival 68.9% vs 77.5% White
20
In India, rural women breast cancer 5-year survival 52% vs urban 70%
21
In South Africa, Black women 5-year survival 52% vs White 86%
22
US men with breast cancer 5-year survival 82.9% (2014-2020)
23
In China, urban vs rural breast cancer survival disparity: urban 79.2% vs rural 68.7% 5-year
24
Low SES US women 5-year breast cancer survival 87% vs high SES 93%
25
In Europe, migrant women breast cancer survival lower by 10-15% than natives
26
US obese women (BMI>30) 5-year survival 89% vs normal weight 92%
27
Smoking women US breast cancer 5-year survival reduced by 30%
Interpretation
Demographic Specific Survival Rates Interpretation
In the Demographic Specific Survival Rates data, the 5-year breast cancer survival in the US remains high across age and race groups, ranging from 81.7% for Black women to 92.8% for women ages 50 to 69 and to 92.4% for non-Hispanic White women, with women under 50 at 89.2% and 70+ at 88.1%.
02 · Category
Molecular Subtype Survival Rates28 stats
01
Triple-negative breast cancer (TNBC) 5-year survival rate is 77% overall, dropping to 12% for metastatic
02
HER2-positive breast cancer 5-year survival improved to 90.3% with targeted therapy (2014-2020 US)
03
Luminal A subtype 5-year survival 91-95%
04
Luminal B subtype 5-year survival ~85%
05
Hormone receptor-positive (HR+) breast cancer 5-year survival 93%
06
HR+/HER2- subtype 5-year survival 94.5%
07
TNBC localized stage 5-year survival 91%, but distant 11%
08
HER2-enriched subtype 5-year survival 80-85% post-trastuzumab
09
Inflammatory breast cancer (often HER2+) 5-year survival 41%
10
In US, ER-positive breast cancer 5-year survival 93.7%
11
ER-negative 5-year survival 82.5% US
12
PR-positive 5-year survival 92.9%, PR-negative 85.4%
13
HER2-positive US 5-year survival 90.9%
14
Triple-positive (HR+/HER2+) 5-year survival ~90%
15
In Europe, TNBC 5-year survival 76%
16
Luminal A Europe 5-year survival 94%
17
Basal-like subtype (subset of TNBC) 5-year survival 62%
18
In Asian populations, HER2+ breast cancer survival 85% at 5 years
19
TNBC in Black women 5-year survival 68%
20
HR+ tumors in postmenopausal women 5-year survival 95%
21
BRCA1-mutated breast cancer 5-year survival 85% if early detection
22
In young women, TNBC subtype 5-year survival 77%
23
Post-neoadjuvant therapy, HER2+ pathologic complete response leads to 95% 5-year survival
24
Luminal B/HER2- 5-year survival 82% without optimal endocrine therapy
25
In metastatic setting, HR+ metastatic 5-year survival 36%
26
TNBC metastatic median survival 12-18 months
27
Surgery alone for early HR+ breast cancer yields 90% 10-year survival
28
With adjuvant chemotherapy for node-positive HER2+ , 5-year survival increases to 88%
Interpretation
Molecular Subtype Survival Rates Interpretation
Across molecular subtype survival rates, targeted and hormone responsive cancers show consistently high 5 year outcomes such as HER2 positive at 90.3% and HR plus at 93%, while triple negative stands out as far lower with only 12% survival once metastatic.
03 · Category
Overall Survival Rates30 stats
01
The 5-year relative survival rate for all stages of female breast cancer combined in the United States from 2014-2020 is 91.4%
02
The 10-year overall survival rate for breast cancer patients diagnosed between 2000-2010 in Europe is approximately 81%
03
In Canada, the 5-year net survival rate for breast cancer in women from 2015-2017 is 88.6%
04
The age-standardized 5-year survival rate for breast cancer in Australia (2008-2012) is 89.7% for females
05
UK's 5-year survival rate for breast cancer in females diagnosed 2016-2020 is 87.7%
06
In Japan, the 5-year relative survival rate for breast cancer (2006-2008) is 89.8%
07
Brazil's 5-year survival rate for breast cancer in women (2000-2010) is around 71%
08
In India, the 5-year overall survival rate for breast cancer is 66.1% as per recent hospital-based data
09
South Africa's 5-year survival rate for breast cancer (1995-2004) is 58% for women
10
The global average 5-year survival rate for breast cancer is estimated at 80-85% in high-income countries
11
In the US, the 5-year survival for invasive female breast cancer (2013-2019) is 91.0%
12
France reports a 5-year survival rate of 87% for breast cancer in women (2010-2015)
13
Germany's 5-year relative survival for breast cancer (2009-2013) is 88.2%
14
Italy's 5-year survival rate for breast cancer females (2010-2014) is 87%
15
Sweden's 10-year breast cancer survival rate (2000-2004 cohort) is 79%
16
In China, 5-year survival for breast cancer (2003-2005) is 73.1%
17
Mexico's 5-year survival rate for breast cancer is 79.5% (2000-2004)
18
Russia's 5-year survival for female breast cancer is 63.4%
19
In Egypt, hospital-based 5-year survival for breast cancer is 62%
20
Nigeria reports a 5-year survival rate of 10-30% for breast cancer due to late diagnosis
21
In the US, 20-year survival for localized breast cancer is 89%
22
Europe's mean 5-year survival for breast cancer improved from 82% (1995-99) to 87% (2005-09)
23
Australia's 10-year survival for breast cancer (2007-2011) is 79.3%
24
Canada's 10-year net survival for breast cancer (2005-2007) is 79.2%
25
UK's one-year survival for breast cancer is 96%
26
Japan's 10-year survival for breast cancer (2001-2003) is 82.7%
27
US Hispanic women's 5-year breast cancer survival is 89.4% (2014-2020)
28
In low-income countries, 5-year breast cancer survival averages below 40%
29
Global 5-year survival for breast cancer in high HDI countries is 90%
30
In the US, 5-year survival for in situ breast cancer is 99.7% (2014-2020)
Interpretation
Overall Survival Rates Interpretation
Across overall survival rates for female breast cancer, survival stays high and fairly consistent internationally, with 5-year rates around the low to high 80s in countries like the United States (91.4%) and the UK (87.7%) and similarly strong figures in Japan (89.8%) and Canada (88.6%) even as longer follow up in Europe shows about 81% at 10 years.
More related reading
04 · Category
Stage Based Survival Rates30 stats
01
The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) in the US (2014-2020) is 99.3%
02
For regional breast cancer (spread to regional lymph nodes) 5-year survival in US (2014-2020) is 86.6%
03
Distant metastatic breast cancer 5-year survival in US (2014-2020) is 31.2%
04
Stage I breast cancer 5-year survival rate is 98-100% globally in high-resource settings
05
Stage II breast cancer 5-year survival is 90-95%
06
Stage III (locally advanced) breast cancer 5-year survival is 70-80%
07
Stage IV breast cancer median survival is 29 months, with 5-year rate ~25%
08
In SEER data (2012-2018), stage 0 (DCIS) 5-year survival is 99%
09
Localized invasive breast cancer 10-year survival is 89.2% in US
10
Regional stage breast cancer 10-year survival is 68.9% (US 2014-2020)
11
Distant stage 10-year survival for breast cancer is 14.6% in US
12
In Europe (EUROCARE-5), stage I breast cancer 5-year survival is 99%
13
Stage II breast cancer in UK 5-year survival is 93%
14
Stage III UK 5-year survival for breast cancer is 78%
15
Stage IV UK 5-year survival is 27%
16
In Australia, localized breast cancer 5-year survival is 99.1%
17
Regional stage in Australia 5-year survival is 89.2%
18
Distant stage Australia 5-year survival 29.8%
19
In Canada, stage I breast cancer 5-year survival >99%
20
Stage II Canada 5-year survival 95%
21
Stage III Canada 5-year survival 80%
22
Stage IV Canada 5-year survival 25%
23
Japan stage 0 breast cancer 10-year survival 98.5%
24
Stage I Japan 10-year survival 95.2%
25
In India, stage I breast cancer 5-year survival 85-90%
26
Stage III India 5-year survival ~50%
27
Stage IV India 5-year survival 10-20%
28
In Brazil, localized breast cancer 5-year survival 92.4%
29
Regional Brazil 5-year survival 82.1%
30
In China, early-stage (I-II) breast cancer 5-year survival 91.6%
Interpretation
Stage Based Survival Rates Interpretation
Across stage based survival rates, breast cancer outcomes drop sharply with spread, from a 99.3% 5-year survival for localized disease to 86.6% for regional and just 31.2% for distant metastatic cancer in the US from 2014 to 2020.
05 · Category
Treatment And Prognostic Factor Survival Rates23 stats
01
Breast cancer patients receiving tamoxifen have 15% reduced mortality, translating to 84% 10-year survival for ER+
02
Trastuzumab for HER2+ early breast cancer improves 5-year survival from 75% to 90%
03
Radiation after lumpectomy increases 10-year survival by 3.6% to 91.7%
04
Neoadjuvant chemotherapy for stage III breast cancer improves 5-year survival to 75%
05
Endocrine therapy for HR+ metastatic disease median survival 4-5 years
06
CDK4/6 inhibitors with endocrine therapy boost PFS, 5-year OS ~70% in advanced HR+
07
Low tumor grade (grade 1) breast cancer 5-year survival 99%
08
High grade (grade 3) 5-year survival 86%
09
Node-negative breast cancer 10-year survival 85-90% with adjuvant therapy
10
1-3 positive nodes 10-year survival 75% with chemo
11
Ki-67 low proliferation (<14%) HR+ breast cancer 10-year survival 94%
12
High Ki-67 (>30%) 10-year survival 74%
13
Oncotype DX score <11: 10-year distant recurrence 4%, survival >95%
14
Oncotype DX 26-100: chemo benefit increases survival by 5-10%
15
Sentinel lymph node biopsy vs axillary dissection: equivalent survival 91% at 8 years
16
PARP inhibitors for BRCA-mutated metastatic TNBC improve median survival to 22 months
17
Immunotherapy (pembrolizumab) for PD-L1+ TNBC metastatic: OS 23 months vs 16.1
18
Comorbidity index 0: 5-year survival 92%, index 3+: 70%
19
Screen-detected breast cancer 5-year survival 96% vs symptomatic 82%
20
Interval cancers post-mammography 5-year survival 78%
21
Mastectomy vs lumpectomy + radiation: 20-year survival 81.2% vs 82.8%
22
Adjuvant bisphosphonates for postmenopausal ER+ reduce recurrence by 18%, survival benefit 9%
23
Exercise post-diagnosis improves 5-year survival by 40% reduction in mortality
Interpretation
Treatment And Prognostic Factor Survival Rates Interpretation
Across Treatment And Prognostic Factor Survival Rates, the biggest survival gains come from targeted therapy and proper sequencing, with tamoxifen bringing ER+ patients to 84% 10-year survival, trastuzumab lifting HER2+ 5-year survival from 75% to 90%, and adding radiation after lumpectomy pushing 10-year survival to 91.7%.
report visual · Breakdown
Breast cancer survival varies by stage and distance from spread
Survival is highest for localized breast cancer and drops sharply for distant metastatic disease.
85.2%
American Indian/Alaska Native women 5-year survival 85.2% US
14.6%
Distant stage 10-year survival for breast cancer is 14.6% in US
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Breast Cancer Survival Rate Statistics. Gitnux. https://gitnux.org/breast-cancer-survival-rate-statistics
MLA
Christopher Morgan. "Breast Cancer Survival Rate Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-survival-rate-statistics.
Chicago
Christopher Morgan. 2026. "Breast Cancer Survival Rate Statistics." Gitnux. https://gitnux.org/breast-cancer-survival-rate-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level